Trial Profile
A retrospective, observational study to assess outcomes in patients treated with first-line bevacizumab-containing therapy for human epidermal growth factor receptor (HER)2-negative metastatic breast cancer (mBC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Mar 2017 New trial record
- 01 Mar 2017 Results assessing outcomes in patients treated with first-line bevacizumab-containing therapy for metastatic breast cancer and subgroup analysis based on patient characteristics published in the Anticancer Research